Clinical Review of Dysautonomia and its Contribution to Long COVID and Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome
Featured in this article
Dysautonomia, a dysfunction of the autonomic nervous system (ANS), is a prevalent and debilitating feature in both Long COVID and ME/CFS. While historically under-recognized in ME/CFS, the emergence of Long COVID has significantly accelerated research into post-viral autonomic dysfunction. Both conditions share striking similarities in their clinical presentation, including profound fatigue, "brain fog," orthostatic intolerance (OI), and post-exertional malaise (PEM), all of which are significantly influenced by dysautonomia.
Key shared pathophysiological mechanisms include neuroinflammation, immune dysregulation (often with autoimmune components), and endothelial dysfunction leading to impaired microcirculation. Postural Orthostatic Tachycardia Syndrome (POTS) is a particularly common manifestation of dysautonomia in both populations. Diagnosis relies on thorough clinical assessment and objective autonomic testing, though PEM presents unique challenges to traditional exercise-based tests. Management requires a comprehensive, individualized approach emphasizing non-pharmacological interventions (e.g., fluid/salt intake, compression, pacing), and carefully selected pharmacological agents.
A crucial distinction in management is the absolute necessity of preventing PEM, which contraindicates standard graded exercise therapy. Future research needs to focus on specific mechanisms, improved diagnostics, and robust clinical trials for targeted therapies, leveraging insights across both conditions.
Key themes and most important ideas
I. Understanding Dysautonomia
The Autonomic Nervous System (ANS) regulates involuntary bodily functions (heart rate, blood pressure, digestion, thermoregulation) via two branches: the Sympathetic Nervous System (SNS - "fight or flight") and Parasympathetic Nervous System (PSNS - "rest and digest"). Dysautonomia occurs when the ANS malfunctions, leading to imbalanced signals and a wide spectrum of multi-system symptoms. It affects over 70 million people worldwide and can be primary (inherited) or secondary (acquired, e.g., from infections, autoimmune diseases).
Common symptoms include:
- Orthostatic Intolerance (OI): Dizziness, lightheadedness, presyncope/syncope upon standing.
- Cardiovascular: Tachycardia, palpitations, labile blood pressure, orthostatic hypotension.
- Neurological/Cognitive: "Brain fog," headaches, visual disturbances, fatigue.
- Sudomotor: Abnormal sweating.
- Gastrointestinal: Nausea, bloating, constipation, diarrhea.
- Other: Exercise intolerance, sleep disturbances, shortness of breath, chronic pain.
Postural Orthostatic Tachycardia Syndrome (POTS)
POTS is a common form of dysautonomia, defined by orthostatic intolerance symptoms and a sustained heart rate increase of ≥30 bpm (adults) or ≥40 bpm (adolescents) within 10 minutes of standing, without orthostatic hypotension. It is a syndrome with several subtypes:
- Neuropathic POTS: Damage to small nerve fibers regulating vasoconstriction, leading to venous pooling.
- Hyperadrenergic POTS: Elevated norepinephrine levels reflecting sympathetic overactivity, causing prominent palpitations, tremors, anxiety.
- Hypovolemic POTS: Abnormally low blood volume, triggering compensatory tachycardia.
- Autoimmune POTS: Autoantibodies targeting autonomic receptors (e.g., adrenergic, muscarinic, gAChR) disrupting signaling. Understanding these subtypes is crucial for personalized treatment.
II. Dysautonomia in Long COVID
Dysautonomia, particularly cardiovascular autonomic dysfunction (CVAD), is a significant and common component of Long COVID, affecting up to one-third of highly symptomatic patients. POTS is frequently diagnosed in 2-14% of COVID-19 survivors, with 9-61% experiencing POTS-like symptoms.
A UK study using the NASA Lean Test (NLT) in Long COVID clinics found 15% had objectively abnormal NLTs (7% POTS, 8% orthostatic hypotension). Strikingly, 45% of those with objective autonomic dysfunction had no previously reported symptoms of orthostatic intolerance, highlighting the risk of underdiagnosis if relying solely on patient report.
Pathophysiological Underpinnings in Long COVID:
- Viral-induced Autonomic Damage, Inflammation, and Cytokine Dysregulation: SARS-CoV-2 may directly damage autonomic structures or cause sustained inflammation. Elevated inflammatory cytokines (IL-6, CRP) correlate with autonomic dysfunction. Neuroinflammation, involving dysregulated brain microglia, also contributes.
- Autoimmune Mechanisms and Autoantibodies: SARS-CoV-2 can trigger autoantibodies against GPCRs (α1/β2-adrenergic, AT1R, M2 muscarinic acetylcholine receptors), vasoactive peptides (Endothelin Type A Receptor - ETAR), and ganglionic acetylcholine receptors (gAChR), disrupting autonomic signaling.
- Endothelial Dysfunction, Microvascular Contributions, and Microclots: Damage to endothelial cells impairs vascular tone and coagulation. Persistent "fibrinaloid" microclots are hypothesized to obstruct microcapillaries, leading to tissue hypoxia, compensatory tachycardia, and fatigue.
- The "Multi-Hit Model": This model proposes that dysautonomia in Long COVID may result from a pre-existing genetic vulnerability (e.g., in ion channels) combined with SARS-CoV-2 infection as an immune trigger, leading to exacerbated ANS dysfunction.
III. Dysautonomia in ME/CFS
Autonomic disturbances have long been recognized in ME/CFS, a serious neuroimmune illness. POTS is a frequent comorbidity, found in ~27% of ME/CFS patients in some studies. Objective evidence includes consistently higher heart rates, diminished nocturnal heart rate dips, and reduced heart rate variability (HRV) and baroreflex sensitivity (BRS), which correlate with fatigue severity.
ME/CFS patients with POTS can exhibit distinct hemodynamic profiles during tilt testing: one with limited HR increase and large stroke volume decrease (suggesting venous pooling), and another with pronounced HR increase but smaller stroke volume decrease (suggesting hyperadrenergic response).
Pathophysiological Insights in ME/CFS:
- Neuroinflammation, Immune Dysregulation, and Cytokine Profiles: Chronic low-grade inflammation, immune activation (e.g., increased NF-$\kappa$B, COX-2, iNOS), and altered cytokine profiles (e.g., elevated TGF-β, various proinflammatory cytokines) are observed. Glial cell activation in the CNS is also implicated.
- Autoimmunity and Autonomic Receptor Antibodies: Autoantibodies against neuronal components and neurotransmitters are being investigated. Autoantibodies to gAChR and α1-adrenergic receptors, similar to those in post-viral POTS, may play a role. B-cell depletion therapy (Rituximab) has shown benefit in some ME/CFS patients, supporting an autoimmune basis.
- Altered Hemodynamics, Baroreflex Sensitivity, and Heart Rate Variability (HRV): Reduced HRV and BRS are common and correlate with fatigue. Higher resting/standing heart rates and blunted nocturnal heart rate falls indicate persistent sympathetic predominance.
- Endothelial Dysfunction and Impaired Cerebral Perfusion: Elevated Endothelin-1 (ET-1) and VCAM-1 suggest endothelial damage. Impaired cerebral perfusion ("reduced blood flow to the brain") is a significant finding contributing to "brain fog" and OI.
IV. Comparative Analysis: Long COVID vs. ME/CFS
There are striking overlaps and some subtle distinctions in dysautonomia between Long COVID and ME/CFS:
Overlapping Features:
- Prominence of Dysautonomia/POTS: Both frequently feature POTS/OI as a major clinical issue.
- Shared Symptom Clusters: Debilitating fatigue, "brain fog," orthostatic intolerance, PEM, sleep disturbances, headaches, GI issues are common to both.
- Similar Autonomic Dysfunction Profiles: Objective tests show comparable reductions in HRV and BRS, correlating with fatigue. Both show abnormal cerebral blood flow reductions during tilt testing.
- Shared Pathophysiological Themes: Neuroinflammation, immune dysregulation/autoimmunity, endothelial dysfunction, and often a post-infectious trigger are common to both. The "multi-hit model" for Long COVID may also apply to post-infectious ME/CFS.
Potential Distinctions:
- Specific Viral Trigger and Immune Response: Long COVID is definitively triggered by SARS-CoV-2, which may elicit a unique autoantibody signature (e.g., higher ETAR autoantibodies). ME/CFS has varied or unknown triggers.
- Autonomic Responsiveness: One study noted HRV normalization during slow breathing in Long COVID patients but not ME/CFS patients, suggesting subtle differences in autonomic plasticity.
- PEM Symptom Nuances: While PEM is core to both, ME/CFS patients may report more unrefreshing sleep and flu-like symptoms during PEM, while Long COVID patients may report more respiratory symptoms. However, overall severity and duration appear similar.
Impact on Core Symptoms: In both conditions, dysautonomia is intrinsically linked to and exacerbates fatigue, "brain fog" (due to reduced/unstable cerebral blood flow), and orthostatic intolerance. For PEM, dysautonomia contributes by impairing the body's ability to respond to and recover from exertion, and PEM in turn worsens autonomic symptoms.
V. Diagnostic Challenges and Clinical Assessment
Recognizing dysautonomia in Long COVID and ME/CFS is challenging due to significant symptom overlap with the conditions themselves. A high index of suspicion is needed for patients reporting postural symptom worsening or unexplained multi-system complaints. Crucially, objective autonomic dysfunction can be present even without classic patient-reported orthostatic symptoms, necessitating proactive screening.
Key Diagnostic Tests:
- Orthostatic Vital Signs: Basic screening for HR/BP changes on standing.
- Tilt Table Test (TTT): Gold standard for POTS, but can provoke PEM.
- NASA Lean Test (NLT): A 10-minute active standing test, recommended for routine Long COVID screening, as it can identify OI even without reported symptoms.
- Autonomic Reflex Screen (Cardiovagal, Adrenergic, Sudomotor): Assesses different ANS branches.
- Heart Rate Variability (HRV) & Baroreflex Sensitivity (BRS) Analysis: Objective measures of autonomic tone and adaptability, often reduced in both conditions and correlating with fatigue.
Diagnostic Considerations: Tests must be interpreted within the clinical context, considering functional limitations and the risk of triggering PEM. Modified protocols (e.g., shorter TTTs) may be necessary. "Normal" results do not exclude intermittent or atypical dysfunction. Future diagnostics may involve biomarker-driven stratification (e.g., autoantibodies).
Co-managing Comorbid Conditions:
Dysautonomia frequently coexists with conditions like hypermobile Ehlers-Danlos Syndrome (hEDS), Mast Cell Activation Syndrome (MCAS), and fibromyalgia, whose symptoms extensively overlap. Differentiating primary dysautonomia from secondary or co-occurring features is complex and requires a multidisciplinary approach.
VI. Management and Therapeutic Strategies
Management is comprehensive and highly individualized, combining non-pharmacological and pharmacological approaches.
Non-Pharmacological Interventions:
- Fluid and Electrolyte Management: Increased fluid (2-3 L/day) and sodium (5-10g/day) intake to optimize intravascular volume.
- Compression Therapy: Medical-grade compression stockings/leggings and abdominal binders to reduce venous pooling.
- Lifestyle Adjustments: Avoiding prolonged standing, hot environments, dehydration, alcohol, and large carb-heavy meals. Using physical counter-maneuvers (e.g., leg crossing). Sleeping with head of bed elevated.
- Exercise Rehabilitation:For POTS without PEM: Gradual, progressive recumbent exercise (e.g., Levine Protocol) can be beneficial.
- For ME/CFS and Long COVID with PEM:Standard graded exercise therapy (GET) is contraindicated and potentially harmful. Instead, meticulous pacing and energy management (staying within the "energy envelope") are paramount to prevent PEM crashes. Exercise, if tolerated, must be highly individualized, starting very low (even minutes) with recumbent activities, and adjusted based on symptom response (especially delayed PEM).
Pharmacological Treatments:
- Blood Volume Expansion/Vasoconstriction:Fludrocortisone: Increases plasma volume.
- Midodrine: Peripheral vasoconstrictor.
- Droxidopa: Increases norepinephrine levels.
- Heart Rate Modulating Agents:Beta-blockers (low dose): Reduce heart rate, especially in hyperadrenergic POTS.
- Ivabradine: Selectively slows heart rate without affecting BP.
- Neuromodulatory Agents:Pyridostigmine: Enhances cholinergic neurotransmission.
- Atomoxetine: Norepinephrine reuptake inhibitor, improves sympathetic tone.
- Emerging and Other Therapies (mechanism-based):Immunomodulators: IVIG (investigational for autoimmune dysautonomia), Rituximab (for B-cell mediated autoimmunity in ME/CFS subgroups).
- Ion Channel Inhibitors/Modulators: Guanfacine (often with NAC) for sympathetic overdrive and neuroinflammation.
- Low-Dose Naltrexone (LDN): Anti-inflammatory, immunomodulatory effects for neuroinflammation, pain, fatigue.
- Stellate Ganglion Block: Investigational for sympathetic overactivity.
Medication Sensitivity:
Patients with ME/CFS and Long COVID often show heightened sensitivity to medications, experiencing adverse effects at standard or even sub-therapeutic doses. Clinicians commonly "start low and go slow" with dosing. More research is needed to understand mechanisms and guide safe pharmacotherapy.
Impact on Overarching Symptoms:
Treating dysautonomia can significantly improve fatigue, "brain fog," and overall functional capacity by stabilizing cardiovascular function, improving cerebral blood flow, and reducing the burden of orthostatic symptoms. However, any improvements must be carefully managed to prevent PEM.
Role of Multidisciplinary Care:
A multidisciplinary team (cardiologists, neurologists, immunologists, physical/occupational therapists, psychologists, dietitians) is often essential for comprehensive assessment and integrated management of the multi-system nature of these illnesses.
VII. Conclusion and Future Directions
Dysautonomia, particularly POTS, is a core pathophysiological component of both Long COVID and ME/CFS, significantly contributing to debilitating symptoms like fatigue, brain fog, OI, and PEM. The rapid growth of Long COVID research has highlighted shared mechanisms (neuroinflammation, autoimmunity, endothelial dysfunction) and accelerated understanding of post-viral chronic illness.
Clinical Implications:
- Heightened Awareness: Clinicians must actively consider and screen for dysautonomia in Long COVID and ME/CFS.
- Individualized Management: Treatment must be tailored to the patient's specific presentation, POTS subtype, and PEM status.
- PEM-Aware Care: Strict pacing and energy conservation are paramount; standard GET is harmful if PEM is present.
- Multidisciplinary Approach: Essential for comprehensive care.
- Patient Education: Crucial for empowering patients and validating their experiences.
Critical Research Gaps:
- Pathophysiology: Deeper understanding of molecular mechanisms, specific autoantibodies, viral persistence, neuroinflammatory pathways, and genetic predispositions. The role of microclots in ME/CFS needs further exploration.
- Diagnostics: Development of more accessible, less provocative, and highly sensitive diagnostic tools/biomarkers, especially for PEM-sensitive patients. Refinement of diagnostic criteria.
- Treatment: Robust randomized controlled trials for existing and emerging therapies, including immunomodulators and targeted neuromodulators. Evidence-based guidelines for activity management and medication sensitivity.
- Natural History and Prognosis: Longitudinal studies to understand long-term outcomes and predictors.
- PEM Mechanisms: Continued research into the physiological basis of PEM.
- Patient Subgrouping: Identifying distinct endotypes to guide personalized medicine.
The ongoing research momentum from Long COVID offers an unprecedented opportunity to advance understanding and develop effective therapies for both Long COVID and ME/CFS, ultimately improving the lives of millions affected by these complex and devastating conditions.
